Feb 22, 2023 / 05:00PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
So welcome back to our next session. My name is Andrew Baum, I run Global Healthcare here at Citi. Delighted to introduce an old friend, David Berman, David is Head of R&D at Immunocore, before that at Bristol-Myers Squibb and has touched many of the approved immuno-oncology drugs on the market over the years. It's good to have you. Also joined by Clay, who runs IR at Immunocore.
Now what I was going to do is unlike some of the majors, where many of you will be very familiar with the technology in hand because Immunocore developed and markets their own lead product, KIMMTRAK, many of you may be unfamiliar with the technology. So I was just going to hand over to David just to set a common denominator and differentiate the TCR-based approach with the bispecifics, which many of you will be familiar with, which address external antigens.
So David, good to have you here, and over to you for [the scene] setting.
David Berman - Immunocore Holdings plc - Head of
Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit Transcript
Feb 22, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers